No quarterly revenue total was found in enVVeno Medical Corporation's SEC filings.
enVVeno Medical Corporation (NVNO) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. As of Sep 30, 2026 it held $18.5 million in cash and investments and $408,000 in total debt.
Revenue
—
Net income
$-4.37M
+3.8% vs year-ago quarter
Operating cash flow
$-3.18M
+27.6% vs year-ago quarter
Free cash flow
$-4.39M
-18.1% vs prior quarter
EPS
$-6.29
+20.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
694,826
-96.6% vs year-ago quarter
Net cash
$18.06M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- NVNO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Irvine, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1661053
- Former names
- Hancock Jaffe Laboratories, Inc. (until Sep 22, 2021)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$4.5M | -$3.8M | -$4.1M | -$4.0M | -$4.9M |
| Net income | -$4.4M | -$3.6M | -$3.8M | -$3.7M | -$4.5M |
| Diluted EPS | -$6.29 | -$5.37 | -$5.89 | -$6.01 | -$7.89 |
| Operating cash flow | -$3.2M | -$3.5M | -$3.2M | -$3.4M | -$4.4M |
| Free cash flow | — | — | — | — | -$4.4M |
| Total assets | $19.5M | $22.7M | $26.1M | $29.6M | $32.4M |
| Total liabilities | $2.6M | $2.0M | $2.4M | $2.4M | $2.9M |
| Stockholders' equity | $16.9M | $20.7M | $23.7M | $27.1M | $29.4M |
| Cash and investments | $18.5M | $21.5M | $24.9M | $28.2M | $31.0M |
| Total debt | $408,000 | $505,000 | $603,000 | $700,000 | $791,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 14, 2026 | Jul 14, 2026 |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Apr 29, 2026 | Apr 29, 2026 |
| 10-K | Annual report | Mar 26, 2026 | Dec 31, 2025 |
All 415 enVVeno Medical Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.